Common side effects

In US poison-center calls involving kratom (2011–2017, n=1,807), the most frequently reported acute clinical effects were agitation (18.6%), tachycardia (16.9%), drowsiness (13.6%), vomiting (11.2%), and confusion (8.1%) (Post 2019). In routine sub-emergency use, the same opioid-typical cluster dominates: nausea and vomiting (particularly at higher doses or on an empty stomach), constipation, dry mouth, reduced appetite, transient sweating during onset, dizziness on postural changes, and sedation that can impair driving and safety-critical tasks. Most of these track dose directly and usually resolve with a dose reduction.

Serious adverse events

Serious outcomes in US poison-center data are uncommon in isolation but consequential: ~32% of kratom exposures required medical facility admission, and the most frequent serious clinical effects were seizure, coma, and cardiac or respiratory arrest (Post 2019). Case series from upstate New York documented kratom-involved deaths in which toxicology detected only kratom alkaloids, undermining the claim that fatal outcomes always involve other substances (Eggleston 2019). Within that envelope, the specific signals to flag:

Dependence and withdrawal. Regular use produces a withdrawal syndrome paralleling classical opioid withdrawal in structure, with severity tracking cumulative dose (Singh 2014). Concentrated 7-OH products compress the time-to-dependence relative to leaf kratom. See the withdrawal page.
Hepatic injury. Kratom-associated hepatotoxicity has been characterised in multiple case reports, typically presenting as a cholestatic or mixed pattern within 2–8 weeks of initiation or dose escalation. Isolated 7-OH is too new in the consumer market for a dedicated liver-injury signal to be quantified, but the mechanism is unlikely to differ.
Respiratory depression.7-OH’s partial-agonist character confers a softer respiratory ceiling than full mu-agonists at equivalent receptor occupancy. That margin collapses in combination with other CNS depressants — which is the typical overdose-death pattern in federal data (CDC MMWR 2019).
Cardiac effects. Tachycardia and hypertension are the dominant cardiac findings in acute exposures (Post 2019); QT prolongation has been described in case reports but is not a well-characterised routine finding.
Seizure. Reported in roughly 6% of kratom exposures with clinical effects (Post 2019), more often at high doses or in polydrug exposures.

Dangerous interactions

The overwhelming majority of kratom-involved overdose deaths in US surveillance data — 87 of 91 cases in the 2016–2017 CDC analysis — involved at least one other substance, most commonly fentanyl (CDC MMWR 2019). Do not combine 7-OH with:

Alcohol — compounded sedation and respiratory depression; the most common co-ingestant in kratom emergency-department presentations.
Benzodiazepines (alprazolam, diazepam, and congeners) — multiplicative, not additive, CNS depression.
Other opioids (prescription or illicit) — additive receptor occupancy and proportionally higher respiratory-depression risk.
Gabapentinoids, sedating antihistamines, sleep medications — all raise the depressant load.
Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice in meaningful volume) — raise 7-OH exposure from mitragynine-containing products via the metabolic pathway identified by Kruegel 2019 and Kamble 2020.
MAOIs and serotonergic agents — theoretical risk; case-level data is limited but the safer default is to avoid.

Who should avoid 7-OH entirely

Pregnant or breastfeeding individuals. Case reports of neonatal abstinence syndrome in infants of chronic kratom-using mothers place this in the clear-avoid category.
People with active or recent liver disease.Kratom-associated hepatotoxicity is the most common serious adverse event in the published case literature.
Individuals with a history of opioid use disorder or other substance use disorder. Preclinical self-administration data indicates 7-OH has abuse liability in the same range as morphine (Hemby 2019).
Patients on prescription opioids, benzodiazepines, or other CNS depressants.
Minors. Under 18 federally; under 21 in states that have raised the floor.

Reducing risk

Start at the bottom of the beginner range and titrate up slowly, with no other psychoactive substances in the same session.
Buy only from brands that publish current third-party Certificates of Analysismatching the lot number on the package.
Do not drive, operate machinery, or perform safety-critical work until effects have fully resolved — typically six hours after dosing for moderate-to-high doses.
Build non-dosing days into any regular-use pattern. Daily use is the strongest predictor of dependence.
Disclose 7-OH use to prescribers before starting any new medication. CYP3A4 interactions are the most common mechanism.
If you suspect an overdose or severe adverse event, call Poison Control (1-800-222-1222 in the US) or 911. Bring the product packaging to the emergency room.